指南与共识浆细胞疾病造血干细胞移植与细胞治疗

多发性骨髓瘤中CAR T细胞治疗的可及性与可负担性:EBMT立场文件

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper.
指南 / 共识 · Lancet Haematol · 2022-01-01

嵌合抗原受体(CAR)T细胞治疗是多发性骨髓瘤有前景的免疫治疗,首批两款产品获批可能改善结局,但技术复杂且昂贵,对医疗系统和社会构成挑战。本文识别可负担性与可及性两大问题,EBMT的临床研究者、临床医生、护士和患者提出解决方案,作为创新协作策略的一部分,使CAR T细胞治疗惠及所有多发性骨髓瘤患者。

要点

  • CAR T细胞治疗是多发性骨髓瘤有前景的免疫治疗,首批两款产品获批可能改善结局。
  • 该技术复杂且昂贵,对医疗系统和社会构成挑战,尤其在危机时期。
  • EBMT立场文件提出解决方案,作为创新协作策略使CAR T细胞治疗可及于所有患者。

核心结论

  • EBMT立场文件提出创新协作策略的解决方案,以使CAR T细胞治疗可及于所有多发性骨髓瘤患者。

研究设计与样本

  • EBMT立场文件,由临床研究者、临床医生、护士和患者共同参与。

主要发现

  • CAR T细胞治疗可及性在国家间因经济发展水平而异,国家内因优质医疗可及性的结构性差异而异,后者与社会经济地位、种族和生活方式强相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell products could result in improved outcomes. However, it remains a complex and expensive technology, which poses challenges to health-care systems and society in general, especially in times of crises. This potentially accelerates pre-existing inequalities as access to CAR T-cell therapy varies, both between countries, depending on the level of economic development, and within countries, due to structural disparities in access to quality health care-a parameter strongly correlated with socioeconomic status, ethnicity, and lifestyle. Here, we identify two important issues: affordability and access to CAR T-cell treatment. This consensus statement from clinical investigators, clinicians, nurses, and patients from the European Society for Blood and Marrow Transplantation (EBMT) proposes solutions as part of an innovative collaborative strategy to make CAR T-cell therapy accessible to all patients with multiple myeloma.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Gagelmann N, Sureda A, Montoto S, et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. Lancet Haematol. 2022. PMID: 36174641. doi:10.1016/S2352-3026(22)00226-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。